| 2026-08-11 | Press release | BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
| 2026-08-11 | Press release | BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress |
| 2026-08-11 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-11 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-06-22 | 8-K | Form 8-K, Item 5.02 |
| 2026-05-12 | Press release | BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
| 2026-05-12 | Press release | BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress |
| 2026-05-12 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-12 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-29 | 8-K | Form 8-K, Item 5.02 |
| 2026-04-28 | Proxy | Definitive proxy statement |
| 2026-04-23 | 8-K | Form 8-K, Item 5.02 |
| 2026-04-22 | Press release | BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026 |
| 2026-04-22 | Press release | BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman |
| 2026-04-21 | Press release | BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026 |
| 2026-04-21 | Deck | The RAS:PI3Kα Breaker BBO-10203 inhibits PI3Kα/AKT activity in HER2AMP models through non-canonical RAS signaling blocka |
| 2026-04-20 | Press release | BBOT Granted U.S. FDA Fast Track Designation for BBO-11818 for the Treatment of Adult Patients with Advanced KRAS-Mutant Pancreatic Ductal Adenocarcinoma |
| 2026-04-13 | Press release | BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
| 2026-03-26 | 8-K | Form 8-K, Item 5.02 |
| 2026-03-18 | Press release | BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 |
| 2026-03-06 | Press release | BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor |
| 2026-03-05 | Press release | BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress |
| 2026-03-05 | Document | Discovery of BBO-11818, a Potent and Selective Noncovalent Inhibitor of (ON) and (OFF) KRAS with Activity against Multip |
| 2026-03-05 | 8-K | Form 8-K, Item 2.02 results |
| 2026-03-05 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-02-12 | Press release | BBOT to Participate in Upcoming Investor Healthcare Conferences |
| 2026-02-06 | Deck | Corporate Update February 2026 |
| 2026-01-12 | Deck | BridgeBio-Corporate-Presentation-January-2026.pdf |
| 2026-01-07 | Press release | BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs |
| 2026-01-07 | 8-K | Form 8-K, Item 8.01 |
| 2025-12-02 | Deck | BBO-10203, a first-in-class breaker of the RAS:PI3Kα interaction, inhibits tumor growth alone and in combination with fu |
| 2025-11-19 | Deck | BREAKER-101: A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-1 |
| 2025-11-12 | 8-K | Form 8-K, Item 2.02 results |
| 2025-11-12 | 10-Q | Form 10-Q for the quarter ended Sep 30 |
| 2025-08-29 | SEC filing | Form S-1 |
| 2025-08-13 | 8-K | Form 8-K, Item 1.01 |
| 2025-08-06 | 8-K | Form 8-K, Item 7.01 |
| 2025-08-04 | 8-K | Form 8-K, Item 5.07 |
| 2025-08-01 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2025-07-21 | Press release | BBOT Appoints Industry Veteran Uneek Mehra as Chief Financial Officer |